ArticleChinese medical journal2026
Fertility-preserving treatment of endometrial cancer and endometrial atypical hyperplasia for patients with metabolic abnormalities: Challenge or opportunity?
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- Integrated analysis of tumor mechanical microenvironment-based signature reveals prognostic risk and immune landscape in endometrial carcinoma.Genes & diseases · 2026Article
- Tumor-metabolism integrated therapy: A new paradigm for fertility-sparing treatment in endometrial cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Persistent endometrial dysfunction after fertility-sparing treatment for endometrial carcinoma: insights from donor oocyte cycles.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a growing demand for fertility-sparing treatment among young patients with early-stage endometrial cancer (EC) and endometrial atypical hyperplasia (EAH). This study aims to evaluate the efficacy of a regimen that combines anti-estrogen therapy with treatments targeting glucose, lipid, and calcium metabolism in EC and EAH patients.
methodsWe conducted a retrospective analysis of patients with EC and EAH who were treated at Peking University People's Hospital between January 2018 and November 2023. The study investigated the clinical profiles of the patients and assessed the efficacy of different treatment strategies.
resultsA total of 285 patients were enrolled in the study, with 149 receiving anti-estrogen monotherapy and 136 receiving a combination therapy (including metformin, statins, calcium channel blockers [CCBs]). The combination therapy group showed a significantly higher proportion of patients with elevated body mass index, insulin resistance, diabetes, and hypertension compared to anti-estrogen group ( P <0.05), and both groups had similar complete response (CR) time and CR rate. Pathological type of EAH and metformin regimen were protective factors for shorter complete response time ( P <0.05). Subsequent stratified analysis revealed that combination therapy with metformin significantly benefited patients with insulin resistance (hazard ratio [HR] = 1.888, 95% confidence interval [CI]: 1.313-2.713) and diabetes mellitus (HR = 2.749, 95% CI: 1.046-7.299).
conclusionsFertility-sparing treatments for patients with metabolic risk factors may have poor efficacy. However, the integration of anti-estrogen therapy with the metabolic-targeting interventions, like metformin, appears to improve the outcomes of fertility-preserving strategies in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.